DFTX DT120 ODT 100 μg Phase 3 results support 2027 NDA plans
Panorama Phase 3 data for DT120 ODT 100 μg in GAD showed rapid, robust, durable efficacy versus placebo and a favorable safety profile, supporting dose-response and 2027 NDA plans.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.